TY - JOUR AU - Xu, J. X. PY - 2017 DA - 2017// TI - FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-Angiogenic therapy and exploratory predictive biomarker analysis JO - Oncologist VL - 22 ID - Xu2017 ER - TY - JOUR AU - Rini, B. I. PY - 2016 DA - 2016// TI - Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma JO - J Immunother Cancer VL - 4 ID - Rini2016 ER - TY - CHAP ED - Graham, R. PY - 2011 DA - 2011// TI - Committee on standards for developing trustworthy clinical practice guidelines BT - Clinical practice guidelines we can trust PB - National Academies Press CY - Washington, DC ID - ref3 ER - TY - JOUR AU - Kaufman, H. L. PY - 2013 DA - 2013// TI - The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma JO - Nat Rev Clin Oncol VL - 10 ID - Kaufman2013 ER - TY - JOUR AU - Hammers, H. J. PY - 2017 DA - 2017// TI - Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study JO - J Clin Oncol VL - 35 ID - Hammers2017 ER - TY - BOOK AU - Network, N. C. C. PY - 2018 DA - 2018// TI - NCCN categories of evidence and consensus ID - Network2018 ER - TY - JOUR AU - Alsharedi, M. AU - Katz, H. PY - 2018 DA - 2018// TI - Check point inhibitors a new era in renal cell carcinoma treatment JO - Med Oncol VL - 35 ID - Alsharedi2018 ER - TY - JOUR AU - Rini, B. I. PY - 2016 DA - 2016// TI - Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial JO - Lancet Oncol VL - 17 ID - Rini2016 ER - TY - JOUR AU - Motzer, R. J. PY - 2018 DA - 2018// TI - Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma JO - N Engl J Med VL - 378 ID - Motzer2018 ER - TY - JOUR AU - Motzer, R. J. PY - 2019 DA - 2019// TI - Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial JO - Lancet Oncol VL - 20 ID - Motzer2019 ER - TY - JOUR AU - Rini, B. I. PY - 2019 DA - 2019// TI - Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma JO - N Engl J Med VL - 380 ID - Rini2019 ER - TY - JOUR AU - Motzer, R. J. PY - 2019 DA - 2019// TI - Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma JO - N Engl J Med VL - 380 ID - Motzer2019 ER - TY - JOUR AU - Choueiri, T. K. PY - 2019 DA - 2019// TI - Subgroup analysis from JAVELIN renal 101: outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) JO - J Clin Oncol VL - 37 ID - Choueiri2019 ER - TY - JOUR AU - Rini, B. I. PY - 2019 DA - 2019// TI - Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial JO - Lancet VL - 393 ID - Rini2019 ER - TY - JOUR AU - Aung, S. PY - 2015 DA - 2015// TI - High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: extension of OS benefits beyond complete response (CR) and partial response (PR) JO - J Clin Oncol VL - 33 ID - Aung2015 ER - TY - JOUR AU - Motzer, R. J. PY - 2015 DA - 2015// TI - Nivolumab versus Everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 ID - Motzer2015 ER - TY - JOUR AU - Mejean, A. PY - 2018 DA - 2018// TI - CARMENA: cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—results of a phase III noninferiority trial JO - J Clin Oncol VL - 36 ID - Mejean2018 ER - TY - JOUR AU - Choueiri, T. K. PY - 2016 DA - 2016// TI - Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma JO - Clin Cancer Res VL - 22 ID - Choueiri2016 ER - TY - JOUR AU - Heng, D. Y. PY - 2013 DA - 2013// TI - External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study JO - Lancet Oncol VL - 14 ID - Heng2013 ER - TY - JOUR AU - Heng, D. Y. PY - 2009 DA - 2009// TI - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study JO - J Clin Oncol VL - 27 ID - Heng2009 ER - TY - JOUR AU - Campesato, L. F. AU - Merghoub, T. PY - 2017 DA - 2017// TI - Antiangiogenic therapy and immune checkpoint blockade go hand in hand JO - Ann Transl Med VL - 5 ID - Campesato2017 ER - TY - JOUR AU - Atkins, M. B. PY - 2018 DA - 2018// TI - Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial JO - Lancet Oncol VL - 19 ID - Atkins2018 ER - TY - JOUR AU - Choueiri, T. K. PY - 2018 DA - 2018// TI - Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial JO - Lancet Oncol VL - 19 ID - Choueiri2018 ER - TY - JOUR AU - McDermott, D. F. PY - 2018 DA - 2018// TI - Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427 JO - J Clin Oncol VL - 36 ID - McDermott2018 ER - TY - JOUR AU - Plimack, E. R. PY - 2018 DA - 2018// TI - Abstract 48: updated results from a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkmate 016 study from the sixteenth international kidney cancer symposium, 2nd-3rd November 2017, Miami, Florida JO - Kidney Cancer VL - 2 ID - Plimack2018 ER - TY - JOUR AU - Buchbinder, E. I. PY - 2019 DA - 2019// TI - Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition JO - J Immunol Ther Cancer VL - 7 ID - Buchbinder2019 ER - TY - JOUR AU - Ravaud, A. PY - 2016 DA - 2016// TI - Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy JO - N Engl J Med VL - 375 ID - Ravaud2016 ER - TY - JOUR AU - Abdel-Rahman, O. AU - ElHalawani, H. AU - Fouad, M. PY - 2015 DA - 2015// TI - Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis JO - Immunotherapy VL - 7 ID - Abdel-Rahman2015 ER - TY - JOUR AU - Abdel-Rahman, O. AU - ElHalawani, H. AU - Fouad, M. PY - 2015 DA - 2015// TI - Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis JO - Expert Opin Drug Saf VL - 14 ID - Abdel-Rahman2015 ER - TY - JOUR AU - Abdel-Rahman, O. AU - Fouad, M. PY - 2016 DA - 2016// TI - A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors JO - Immunotherapy VL - 8 ID - Abdel-Rahman2016 ER - TY - JOUR AU - Abdel-Rahman, O. AU - Fouad, M. PY - 2016 DA - 2016// TI - Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis JO - Ther Adv Respir Dis VL - 10 ID - Abdel-Rahman2016 ER - TY - JOUR AU - Abdel-Rahman, O. PY - 2016 DA - 2016// TI - Treatment-associated fatigue in Cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis JO - Clin Oncol (R Coll Radiol) VL - 28 ID - Abdel-Rahman2016 ER - TY - JOUR AU - Abdel-Wahab, N. AU - Shah, M. AU - Suarez-Almazor, M. E. PY - 2016 DA - 2016// TI - Adverse events associated with immune checkpoint blockade in patients with Cancer: a systematic review of case reports JO - PLoS One VL - 11 ID - Abdel-Wahab2016 ER - TY - JOUR AU - Velasco, G. PY - 2017 DA - 2017// TI - Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in Cancer patients JO - Cancer Immunol Res VL - 5 ID - Velasco2017 ER - TY - JOUR AU - Ferris, R. L. PY - 2016 DA - 2016// TI - Nivolumab for recurrent squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 375 ID - Ferris2016 ER - TY - JOUR AU - Seiwert, T. Y. PY - 2016 DA - 2016// TI - Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial JO - Lancet Oncol VL - 17 ID - Seiwert2016 ER - TY - JOUR AU - Weber, J. S. PY - 2008 DA - 2008// TI - Phase I/II study of ipilimumab for patients with metastatic melanoma JO - J Clin Oncol VL - 26 ID - Weber2008 ER - TY - JOUR AU - Wolchok, J. D. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 ID - Wolchok2009 ER - TY - JOUR AU - Seymour, L. PY - 2017 DA - 2017// TI - iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics JO - Lancet Oncol VL - 18 ID - Seymour2017 ER - TY - JOUR AU - Schwartz, L. H. PY - 2016 DA - 2016// TI - RECIST 1.1-update and clarification: from the RECIST committee JO - Eur J Cancer VL - 62 ID - Schwartz2016 ER - TY - JOUR AU - Hodi, F. S. PY - 2018 DA - 2018// TI - Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of Cancer immunotherapy JO - J Clin Oncol VL - 36 ID - Hodi2018 ER - TY - JOUR AU - Tazdait, M. PY - 2018 DA - 2018// TI - Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria JO - Eur J Cancer VL - 88 ID - Tazdait2018 ER - TY - JOUR AU - Anagnostou, V. PY - 2017 DA - 2017// TI - Immuno-oncology trial endpoints: capturing clinically meaningful activity JO - Clin Cancer Res VL - 23 ID - Anagnostou2017 ER - TY - JOUR AU - George, S. PY - 2016 DA - 2016// TI - Safety and efficacy of Nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial JO - JAMA Oncol VL - 2 ID - George2016 ER - TY - JOUR AU - Escudier, B. PY - 2017 DA - 2017// TI - Treatment beyond progression in patients with advanced renal cell carcinoma treated with Nivolumab in CheckMate 025 JO - Eur Urol VL - 72 ID - Escudier2017 ER - TY - JOUR AU - McDermott, D. F. PY - 2018 DA - 2018// TI - Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma JO - Nat Med VL - 24 ID - McDermott2018 ER - TY - JOUR AU - Escudier, B. PY - 2017 DA - 2017// TI - CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for Nivolumab versus Everolimus in advanced renal cell carcinoma JO - Eur Urol VL - 72 ID - Escudier2017 ER - TY - JOUR AU - Joseph, R. W. PY - 2015 DA - 2015// TI - PD-1 and PD-L1 expression in renal cell carcinoma with Sarcomatoid differentiation JO - Cancer Immunol Res VL - 3 ID - Joseph2015 ER - TY - JOUR AU - Choueiri, T. K. PY - 2015 DA - 2015// TI - Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial JO - Clin Cancer Res VL - 21 ID - Choueiri2015 ER - TY - JOUR AU - Atkins, M. B. PY - 2017 DA - 2017// TI - IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun) JO - J Clin Oncol VL - 35 ID - Atkins2017 ER - TY - BOOK AU - Rini, B. PY - 2018 DA - 2018// TI - Molecular correlates differentiate response to atezolizumab + bevacizumab vs sunitinib ID - Rini2018 ER - TY - JOUR AU - Kulangara, K. PY - 2017 DA - 2017// TI - Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx JO - J Clin Oncol VL - 35 ID - Kulangara2017 ER - TY - JOUR AU - Choueiri, T. K. PY - 2019 DA - 2019// TI - Biomarker analyses from JAVELIN renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) JO - J Clin Oncol VL - 37 ID - Choueiri2019 ER - TY - JOUR AU - McDermott, D. F. AU - Motzer, R. J. AU - Rini, B. E. A. PY - 2018 DA - 2018// TI - CheckMate 214 retrospective analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features JO - Clin Adv Hematol Oncol VL - 16 ID - McDermott2018 ER - TY - JOUR AU - Patard, J. J. PY - 2005 DA - 2005// TI - Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience JO - J Clin Oncol VL - 23 ID - Patard2005 ER - TY - JOUR AU - Giles, R. H. PY - 2017 DA - 2017// TI - Recommendations for the Management of Rare Kidney Cancers JO - Eur Urol VL - 72 ID - Giles2017 ER - TY - JOUR AU - Moch, H. PY - 2016 DA - 2016// TI - The 2016 WHO classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular Tumours JO - Eur Urol VL - 70 ID - Moch2016 ER - TY - JOUR AU - McDermott, D. F. PY - 2019 DA - 2019// TI - First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B JO - J Clin Oncol VL - 37 ID - McDermott2019 ER - TY - JOUR AU - Koshkin, V. S. PY - 2018 DA - 2018// TI - Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma JO - J Immunother Cancer VL - 6 ID - Koshkin2018 ER - TY - JOUR AU - Johnson, D. B. PY - 2016 DA - 2016// TI - Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders JO - JAMA Oncol VL - 2 ID - Johnson2016 ER - TY - JOUR AU - Kyi, C. PY - 2014 DA - 2014// TI - Ipilimumab in patients with melanoma and autoimmune disease JO - J Immunother Cancer VL - 2 ID - Kyi2014 ER - TY - JOUR AU - Lee, B. PY - 2016 DA - 2016// TI - The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma JO - Ann Oncol VL - 27 ID - Lee2016 ER - TY - JOUR AU - Gettings, E. J. AU - Hackett, C. T. AU - Scott, T. F. PY - 2015 DA - 2015// TI - Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma JO - Mult Scler VL - 21 ID - Gettings2015 ER - TY - JOUR AU - Menzies, A. M. PY - 2017 DA - 2017// TI - Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab JO - Ann Oncol VL - 28 ID - Menzies2017 ER - TY - JOUR AU - Arbour, K. C. PY - 2018 DA - 2018// TI - Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung Cancer JO - J Clin Oncol VL - 36 ID - Arbour2018 ER - TY - JOUR AU - Cella, D. PY - 2016 DA - 2016// TI - Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 17 ID - Cella2016 ER - TY - JOUR AU - Pal, S. K. PY - 2019 DA - 2019// TI - Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC) JO - J Clin Oncol VL - 37 ID - Pal2019 ER - TY - JOUR AU - Escudier, B. PY - 2018 DA - 2018// TI - Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC) JO - J Clin Oncol VL - 36 ID - Escudier2018 ER - TY - JOUR AU - Hegde, P. S. AU - Karanikas, V. AU - Evers, S. PY - 2016 DA - 2016// TI - The where, the when, and the how of immune monitoring for Cancer immunotherapies in the era of checkpoint inhibition JO - Clin Cancer Res VL - 22 ID - Hegde2016 ER -